PT  - JOURNAL ARTICLE
AU  - Warneford-Thomson, Robert
AU  - Shah, Parisha P.
AU  - Lundgren, Patrick
AU  - Lerner, Jonathan
AU  - Abella, Benjamin S.
AU  - Zaret, Kenneth S.
AU  - Schug, Jonathan
AU  - Jain, Rajan
AU  - Thaiss, Christoph A.
AU  - Bonasio, Roberto
TI  - COV-ID: A LAMP sequencing approach for high-throughput co-detection of SARS-CoV-2 and influenza virus in human saliva
AID  - 10.1101/2021.04.23.21255523
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.23.21255523
4099  - http://medrxiv.org/content/early/2021/04/23/2021.04.23.21255523.short
4100  - http://medrxiv.org/content/early/2021/04/23/2021.04.23.21255523.full
AB  - The COVID-19 pandemic has created an urgent need for rapid, effective, and low-cost SARS-CoV-2 diagnostic testing. Here, we describe COV-ID, an approach that combines RT-LAMP with deep sequencing to detect SARS-CoV-2 in unprocessed human saliva with high sensitivity (5–10 virions). Based on a multi-dimensional barcoding strategy, COV-ID can be used to test thousands of samples overnight in a single sequencing run with limited labor and laboratory equipment. The sequencing-based readout allows COV-ID to detect multiple amplicons simultaneously, including key controls such as host transcripts and artificial spike-ins, as well as multiple pathogens. Here we demonstrate this flexibility by simultaneous detection of 4 amplicons in contrived saliva samples: SARS-CoV-2, influenza A, human STATHERIN, and an artificial SARS spike-in. The approach was validated on clinical saliva samples, where it showed 100% agreement with RT-qPCR. COV-ID can also be performed directly on saliva adsorbed on filter paper, simplifying collection logistics and sample handling.Competing Interest StatementR.W-T., C.A.T. and R.B. are inventors on a patent application filed by the University of Pennsylvania related to this work.Funding StatementThis work was internally funded in part by the Rapid Assay Task Force initiative at the University of Pennsylvania.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical saliva samples used for Fig. 2E were obtained and characterized as part of a study at the University of Pennsylvania and collected under Institutional Review Board (IRB)-approved protocols (IRB protocol #842613 and #813913). The saliva used in the remaining experiments was donated by one of the authors. Because it was only used for protocol optimization the Penn IRB has determined that it did not constitute human subjects research and therefore approval was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNext generation sequencing data generated for this study are available at the NCBI GEO with accession GSE172118. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172118